Home

Download

Statistics

Landscape

Help

Contact

	1. Gene summary of enriched editing regions
	2. Tumor-specific enriched editing regions
	Comparison of enriched editing regions between tumor and normal.
	Correlation of enriched editing regions with tumor stages.
	Associations of enriched editing regions with cancer survival.
	3. Enriched editing regions and immune related genes
	4. Enriched editing regions and immune related splicing
	5. Enriched editing regions and immune infiltration
	6. Enriched editing regions and immune gene sets
	Correlation of enriched editing regions with epithelial-mesenchymal transition.
	Correlations of enriched editing regions with hypoxic.
	Associations of enriched editing regions with hallmark gene sets from MSigDB.
	7. Enriched editing regions and drugs
	Correlations between enriched editing regions and drug sensitivity.
	Enriched editing regions targeted by drugs from DrugBank database.

Editing gene: AP5B1 (ImmuneEditome ID:91056)

1. Gene summary of enriched editing regions for AP5B1

Gene summary

Gene information	Gene symbol	AP5B1
	Gene ID	91056
	GeneSynonyms	AP-5\|PP1030
	GeneCytomap	11q13.1
	GeneType	protein-coding
	GeneDescription	AP-5 complex subunit beta-1\|AP-5 complex subunit beta\|adaptor related protein complex 5 beta 1 subunit\|adaptor-related protein complex 5 beta subunit\|beta5
	GeneModificationdate	20230329
	UniprotID	Q2VPB7
	PubMed ID

UCSC image.

Locations of each EERs.

EER	ENST	ENSG	GeneName	Region	Repeat	dsRNA structure
chr11:65775899-65777113:-	ENST00000532090.2	ENSG00000254470.2	AP5B1	UTR3	AluJb,AluSx1,MIRb	chr11:65775899-65777113:-.alignment

Top

2. Tumor-specific enriched editing regions for AP5B1

Comparison of enriched editing regions between tumor and normal.

* P<0.05 and Informative number >=20.

* EER: enriched editing region, EAG: EER-associated genes.

ID_events	cancer	Type	P	Boxplot
chr11:65775899-65777113:-	BRCA	EER	2.1174e-12
ENSG00000254470.2,AP5B1	BRCA	EAG	2.1174e-12
chr11:65775899-65777113:-	COAD	EER	5.2465e-09
ENSG00000254470.2,AP5B1	COAD	EAG	5.2465e-09
chr11:65775899-65777113:-	HNSC	EER	1.1680e-03
ENSG00000254470.2,AP5B1	HNSC	EAG	1.1680e-03
chr11:65775899-65777113:-	KIRC	EER	8.0206e-03
ENSG00000254470.2,AP5B1	KIRC	EAG	8.0206e-03
chr11:65775899-65777113:-	KIRP	EER	2.0618e-04
ENSG00000254470.2,AP5B1	KIRP	EAG	2.0618e-04
chr11:65775899-65777113:-	LUAD	EER	1.5359e-09
ENSG00000254470.2,AP5B1	LUAD	EAG	1.5359e-09
chr11:65775899-65777113:-	LUSC	EER	6.8049e-07
ENSG00000254470.2,AP5B1	LUSC	EAG	6.8049e-07
chr11:65775899-65777113:-	THCA	EER	1.9673e-07
ENSG00000254470.2,AP5B1	THCA	EAG	1.9673e-07

Top

Correlation of enriched editing regions with tumor stages.

* AnovaP<0.05, Pearson P<0.05 and Informative number >=20.

* EER: enriched editing region, EAG: EER-associated genes, Path: Pathological stage, Cli: Clinical stage.

* Only shows the most significant correlation result of EERs/EAGs with either pathological stage or clinical stage according to correlation coefficient (R). For more results, please go to download page.

ID_events	cancer	Type	StageType	AnovaP	P	R	Boxplot
ENSG00000254470.2,AP5B1	KIRC	Path	EAG	4.1115e-03	2.8877e-03	0.1427
chr11:65775899-65777113:-	KIRC	Path	EER	4.1115e-03	2.8877e-03	0.1427

Top

Associations of enriched editing regions with cancer survival.

* Pkm<0.05 and Pcox<0.05.

* EER: enriched editing region, EAG: EER-associated genes.

ID_events	cancer	TypeID	Pkm	Pcox_continuous	HR_continuous	KMPlot
chr11:65775899-65777113:-	LUAD	EER	1.2431e-02	1.3989e-02	7.3737e+00
ENSG00000254470.2,AP5B1	LUAD	EAG	1.2431e-02	1.3989e-02	7.3737e+00

Top

3. Enriched editing regions and immune related genes for AP5B1

Enriched editing regions and immune related genes.

* First, the associations between enriched editing regions and genes were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).

* Second, the gene relationships with immune were tested by three analyses: whether the gene is an immune gene (InnateDB、Immport、Immunome、Immunogenetic Related Information Source (IRIS)), whether the gene is associated with immune infiltration and whether the gene is related to immune gene sets.

* EER: enriched editing region, EAG: EER-associated genes.

* Only shows the most significant correlation result of genes with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.

ID_events

cancer

Type

Gene

beta

FDR

PearsonP

PearsonR

CorrelationPlot

RBP

RBPtargets

ImmuneGene

ImmuneFraction

HallMark

chr11:65775899-65777113:-

KICH

EER

ENSG00000234753,FOXP4-AS1

-0.5711

3.4160e-02

1.4026e-04

-0.4685

T_cells_follicular_helper

chr11:65775899-65777113:-

THCA

EER

ENSG00000132405,TBC1D14

-0.3442

2.2184e-11

5.4186e-21

-0.4277

B_cells_naive

GSVA_HALLMARK_UV_RESPONSE_DN

chr11:65775899-65777113:-

THCA

EER

ENSG00000176986,SEC24C

-0.3301

1.3041e-10

1.5308e-20

-0.4232

NK_cells_activated

GSVA_HALLMARK_PROTEIN_SECRETION

chr11:65775899-65777113:-

KIRC

EER

ENSG00000107185,RGP1

-0.3361

4.1612e-08

1.9171e-14

-0.4106

T_cells_regulatory_(Tregs)

GSVA_HALLMARK_UV_RESPONSE_DN

chr11:65775899-65777113:-

KIRC

EER

ENSG00000101132,PFDN4

0.2842

1.1855e-05

9.4412e-14

0.4004

Eosinophils

GSVA_HALLMARK_MITOTIC_SPINDLE

chr11:65775899-65777113:-

KIRC

EER

ENSG00000100097,LGALS1

0.1927

7.6509e-03

4.0789e-14

0.4058

LGALS1

T_cells_regulatory_(Tregs)

GSVA_HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITION

chr11:65775899-65777113:-

UVM

EER

ENSG00000103335,PIEZO1

-0.3836

1.5289e-02

2.1177e-04

-0.4052

B_cells_naive

GSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALING

chr11:65775899-65777113:-

UVM

EER

ENSG00000166716,ZNF592

-0.3683

2.3802e-02

1.5823e-04

-0.4125

Macrophages_M0

GSVA_HALLMARK_HEME_METABOLISM

chr11:65775899-65777113:-

UVM

EER

ENSG00000090863,GLG1

-0.3292

4.2568e-02

1.7084e-04

-0.4106

Macrophages_M0

GSVA_HALLMARK_TGF_BETA_SIGNALING

More results

Top

4. Enriched editing regions and immune related splicing for AP5B1

Enriched editing regions and immune related splicing.

* First, the associations between enriched editing regions and splicing events were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).

* Second, the splicing relationships with immune were tested by three analyses: whether the splicing event locates in an immune gene (InnateDB、Immport, Immunome and Immunogenetic Related Information Source (IRIS)), whether the splicing event is associated with immune infiltration and whether the splicing event is related to immune gene sets.

* EER: enriched editing region, EAG: EER-associated genes.

* Only shows the most significant correlation result of splicing events with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.

ID_events

cancer

Type

SplicingType

SplicingGene

SplicingChr

SplicingPosition

beta

FDR

PearsonP

PearsonR

CorrelationPlot

RBP

RBPtargets

ImmuneGene

ImmuneFraction

HallMark

ENSG00000254470.2,AP5B1

KIRC

EAG

ENSG00000196199.9

chr13

19646442:19647291:19648421:19648521

0.2740

1.0493e-04

4.3479e-14

0.4060

ADAR;AUH;BCCIP;BUD13;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DICER1;DKC1;EIF4A3;EIF4G2;ELAVL1;ELAVL3;EWSR1;FAM120A;FBL;FMR1;FUS;FXR1;FXR2;GNL3;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPL;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHSRP;LIN28;LIN28B;LSM11;MOV10;MSI1;MSI2;NOP56;NOP58;NUMA1;PRPF8;PTBP1;RANGAP1;RBFOX2;RBM10;RBM27;RC3H1;RNF219;SAFB2;SF3A3;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF10;SRSF3;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;VIM;XRN2;YWHAG;ZNF184

T_cells_regulatory_(Tregs)

GSVA_HALLMARK_HEME_METABOLISM

chr11:65775899-65777113:-

KIRC

EER

ENSG00000196199.9

chr13

19646442:19647291:19648421:19648521

0.2740

9.6361e-05

4.3479e-14

0.4060

T_cells_regulatory_(Tregs)

GSVA_HALLMARK_HEME_METABOLISM

chr11:65775899-65777113:-

KIRP

EER

ENSG00000108799.8

chr17

42717975:42718067:42718453:42718617

0.2550

7.0867e-03

1.2516e-11

0.4361

T_cells_regulatory_(Tregs)

GSVA_HALLMARK_MITOTIC_SPINDLE

ENSG00000254470.2,AP5B1

KIRP

EAG

ENSG00000108799.8

chr17

42717975:42718067:42718453:42718617

0.2550

7.5247e-03

1.2516e-11

0.4361

ADAR;AIFM1;AUH;BCCIP;BUD13;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DICER1;DKC1;EIF4A3;EIF4G2;ELAVL1;ELAVL3;EWSR1;FAM120A;FBL;FMR1;FUS;FXR1;FXR2;GNL3;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPL;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHSRP;LARP7;LIN28;LIN28B;LSM11;MOV10;NONO;NOP56;NOP58;NUMA1;PRPF8;PTBP1;RANGAP1;RBFOX2;RBM10;RBM27;RNF219;SAFB2;SF3A3;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF3;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;VIM;XRN2;YTHDF1;YWHAG;ZNF184

T_cells_regulatory_(Tregs)

GSVA_HALLMARK_MITOTIC_SPINDLE

chr11:65775899-65777113:-

PAAD

EER

MEX

ENSG00000169045.13

chr5

179616157:179616218:179616868:179616958:179620891:179621397:179623036:179623164

0.3718

3.7368e-02

7.5680e-07

0.4120

T_cells_regulatory_(Tregs)

GSVA_HALLMARK_UV_RESPONSE_DN

ENSG00000254470.2,AP5B1

PAAD

EAG

ENSG00000159899.10

chr9

35799617:35799731:35800021:35800157

0.3673

3.5096e-03

7.3412e-10

0.5539

ADAR;BCCIP;BUD13;CSTF2T;DDX42;DDX54;DGCR8;DKC1;EIF4A3;EIF4G2;ELAVL1;FAM120A;FBL;FMR1;FUS;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPL;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHSRP;LIN28B;LSM11;MOV10;MSI1;NONO;NOP56;NOP58;PRPF8;PTBP1;RBFOX2;RBM10;SAFB2;SF3A3;SF3B4;SLTM;SRSF1;SRSF10;SRSF3;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TROVE2;U2AF1;U2AF2;UPF1;XRN2

T_cells_CD4_memory_activated

GSVA_HALLMARK_UV_RESPONSE_DN

chr11:65775899-65777113:-

PAAD

EER

ENSG00000159899.10

chr9

35799617:35799731:35800021:35800157

0.3673

4.0101e-03

7.3412e-10

0.5539

T_cells_CD4_memory_activated

GSVA_HALLMARK_UV_RESPONSE_DN

ENSG00000254470.2,AP5B1

PAAD

EAG

MEX

ENSG00000169045.13

chr5

179616157:179616218:179616868:179616958:179620891:179621397:179623036:179623164

0.3718

3.7965e-02

7.5680e-07

0.4120

ADAR;AIFM1;AUH;BCCIP;BUD13;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DICER1;DKC1;EIF4A3;EIF4G2;ELAVL1;ELAVL3;EWSR1;FAM120A;FBL;FKBP4;FMR1;FTO;FUS;FXR1;FXR2;GNL3;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPL;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHSRP;LARP4B;LARP7;LIN28;LIN28B;LSM11;MOV10;MSI1;MSI2;NONO;NOP56;NOP58;NUMA1;PRPF8;PTBP1;QKI;RANGAP1;RBFOX2;RBM10;RBM27;RC3H1;RNF219;SAFB2;SF3A3;SF3B4;SLBP;SLTM;SMNDC1;SND1;SRSF1;SRSF10;SRSF3;SRSF7;SRSF9;TAF15;TARBP2;TARDBP;TIA1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;VIM;XRN2;YTHDC1;YTHDF1;YWHAG;ZNF184

T_cells_regulatory_(Tregs)

GSVA_HALLMARK_UV_RESPONSE_DN

ENSG00000254470.2,AP5B1

THCA

EAG

ENSG00000136709.7

chr2

127763061:127763159:127764827:127764979

0.3397

9.0150e-10

1.5376e-21

0.4331

ADAR;AIFM1;AUH;BCCIP;BUD13;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DICER1;DKC1;EIF4A3;EIF4G2;ELAVL1;ELAVL3;EWSR1;FAM120A;FBL;FKBP4;FMR1;FTO;FUS;FXR1;FXR2;GNL3;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPL;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHSRP;LARP4B;LARP7;LIN28;LIN28B;LSM11;METTL14;MOV10;MSI1;MSI2;NONO;NOP56;NOP58;NUMA1;PRPF8;PTBP1;QKI;RANGAP1;RBFOX2;RBM10;RBM27;RC3H1;RNF219;SAFB2;SF3A3;SF3B4;SLBP;SLTM;SMNDC1;SND1;SRSF1;SRSF10;SRSF3;SRSF7;SRSF9;TAF15;TARBP2;TARDBP;TIA1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;VIM;XRN2;YTHDC1;YTHDF1;YTHDF2;YWHAG;ZNF184

NK_cells_activated

GSVA_HALLMARK_UV_RESPONSE_DN

chr11:65775899-65777113:-

THCA

EER

ENSG00000136709.7

chr2

127763061:127763159:127764827:127764979

0.3397

1.1582e-09

1.5376e-21

0.4331

NK_cells_activated

GSVA_HALLMARK_UV_RESPONSE_DN

More results

Top

5. Enriched editing regions and immune infiltration for AP5B1

Associations of enriched editing regions with immune infiltration.

* P<0.05 and Informative number >=20.

* EER: enriched editing region, EAG: EER-associated genes.

* Only shows the most significant correlation result of EERs/EAGs with the fraction of different immune cells according to correlation coefficient (R). For more results, please go to download page.

ID_events	cancer	TypeID	ImmuneCell	P	R	CorrelationPlot
chr11:65775899-65777113:-	ACC	EER	T_cells_CD4_naive	1.0244e-03	0.5870
ENSG00000254470.2,AP5B1	ACC	EAG	T_cells_CD4_naive	1.0244e-03	0.5870
chr11:65775899-65777113:-	BLCA	EER	Plasma_cells	5.3164e-04	0.2087
ENSG00000254470.2,AP5B1	BLCA	EAG	Plasma_cells	5.3164e-04	0.2087
chr11:65775899-65777113:-	BRCA	EER	NK_cells_activated	7.7849e-04	0.1104
ENSG00000254470.2,AP5B1	BRCA	EAG	NK_cells_activated	7.7849e-04	0.1104
chr11:65775899-65777113:-	COAD	EER	T_cells_CD4_naive	7.0962e-03	0.1840
ENSG00000254470.2,AP5B1	COAD	EAG	T_cells_CD4_naive	7.0962e-03	0.1840
chr11:65775899-65777113:-	ESCA	EER	Macrophages_M2	2.4246e-03	0.2382
ENSG00000254470.2,AP5B1	ESCA	EAG	Macrophages_M2	2.4246e-03	0.2382
chr11:65775899-65777113:-	GBM	EER	T_cells_CD8	2.4322e-02	0.2100
ENSG00000254470.2,AP5B1	GBM	EAG	T_cells_CD8	2.4322e-02	0.2100
chr11:65775899-65777113:-	HNSC	EER	B_cells_naive	1.4187e-03	-0.1547
ENSG00000254470.2,AP5B1	HNSC	EAG	B_cells_naive	1.4187e-03	-0.1547
chr11:65775899-65777113:-	KICH	EER	Plasma_cells	4.2308e-02	0.2609
ENSG00000254470.2,AP5B1	KICH	EAG	Plasma_cells	4.2308e-02	0.2609
chr11:65775899-65777113:-	KIRC	EER	T_cells_gamma_delta	7.2122e-04	0.1881
ENSG00000254470.2,AP5B1	KIRC	EAG	T_cells_gamma_delta	7.2122e-04	0.1881
chr11:65775899-65777113:-	LAML	EER	T_cells_CD4_memory_resting	4.6135e-03	0.2340
ENSG00000254470.2,AP5B1	LAML	EAG	T_cells_CD4_memory_resting	4.6135e-03	0.2340
chr11:65775899-65777113:-	LGG	EER	NK_cells_resting	1.8512e-03	0.1459
ENSG00000254470.2,AP5B1	LGG	EAG	NK_cells_resting	1.8512e-03	0.1459
chr11:65775899-65777113:-	LIHC	EER	NK_cells_activated	7.1424e-03	0.2306
ENSG00000254470.2,AP5B1	LIHC	EAG	NK_cells_activated	7.1424e-03	0.2306
chr11:65775899-65777113:-	LUAD	EER	T_cells_gamma_delta	1.8661e-08	0.2607
ENSG00000254470.2,AP5B1	LUAD	EAG	T_cells_gamma_delta	1.8661e-08	0.2607
chr11:65775899-65777113:-	LUSC	EER	B_cells_memory	1.6773e-02	0.1109
ENSG00000254470.2,AP5B1	LUSC	EAG	B_cells_memory	1.6773e-02	0.1109
chr11:65775899-65777113:-	OV	EER	Macrophages_M2	3.3033e-02	0.1371
ENSG00000254470.2,AP5B1	OV	EAG	Macrophages_M2	3.3033e-02	0.1371
chr11:65775899-65777113:-	PAAD	EER	NK_cells_resting	1.4950e-02	-0.2098
ENSG00000254470.2,AP5B1	PAAD	EAG	NK_cells_resting	1.4950e-02	-0.2098
chr11:65775899-65777113:-	PCPG	EER	Dendritic_cells_activated	3.9522e-02	-0.2187
ENSG00000254470.2,AP5B1	PCPG	EAG	Dendritic_cells_activated	3.9522e-02	-0.2187
chr11:65775899-65777113:-	PRAD	EER	Neutrophils	1.4802e-02	-0.1372
ENSG00000254470.2,AP5B1	PRAD	EAG	Neutrophils	1.4802e-02	-0.1372
ENSG00000254470.2,AP5B1	READ	EAG	Dendritic_cells_activated	4.5415e-02	0.2287
chr11:65775899-65777113:-	SARC	EER	NK_cells_resting	8.7227e-03	-0.2100
ENSG00000254470.2,AP5B1	SARC	EAG	NK_cells_resting	8.7227e-03	-0.2100
chr11:65775899-65777113:-	SKCM	EER	Plasma_cells	5.6086e-04	0.1663
ENSG00000254470.2,AP5B1	SKCM	EAG	Plasma_cells	5.6086e-04	0.1663
chr11:65775899-65777113:-	STAD	EER	Eosinophils	5.7589e-03	0.1471
ENSG00000254470.2,AP5B1	STAD	EAG	Eosinophils	5.7589e-03	0.1471
ENSG00000254470.2,AP5B1	TGCT	EAG	Plasma_cells	2.5948e-02	0.3088
chr11:65775899-65777113:-	THCA	EER	T_cells_CD4_memory_activated	5.3798e-06	0.2150
ENSG00000254470.2,AP5B1	THCA	EAG	T_cells_CD4_memory_activated	5.3798e-06	0.2150
chr11:65775899-65777113:-	UCEC	EER	T_cells_follicular_helper	4.8567e-03	-0.2882
ENSG00000254470.2,AP5B1	UCEC	EAG	T_cells_follicular_helper	4.8567e-03	-0.2882
chr11:65775899-65777113:-	UVM	EER	Macrophages_M2	2.8873e-02	-0.2460
ENSG00000254470.2,AP5B1	UVM	EAG	Macrophages_M2	2.8873e-02	-0.2460

Top

6. Enriched editing regions and immune gene sets for AP5B1

Correlation of enriched editing regions with epithelial-mesenchymal transition.

* First, the differences of enriched editing regions between Epi and Mes groups (defined by KS-test) were compared (P<0.05 and Informative number >=20).

* Second, the correlations between enriched editing regions and gene set score of HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITION were analyzed (P<0.05 and Informative number >=20).

* EER: enriched editing region, EAG: EER-associated genes.

* Only shows the EERs/EAGs significantly edited between Epi and Mes group.

ID_events

cancer

Type

E2M_P

Boxplot

CorP

CorR

CorrelationPlot

Top

Correlations of enriched editing regions with hypoxic.

* First, there are four hypoxia scores used in the database. The first three hypoxic scores were calculated on three gene sets of Buffa, Ragnum and Winter based on one previous study (PMID: 32024819). One last hypoxia score was defined on HALLMARK_HYPOXIA by GSVA method.

* Second, the correlations enriched editing regions with the four hypoxic scores were analyzed (P<0.05 and Informative number >=20).

* EER: enriched editing region, EAG: EER-associated genes.

* Only shows the EERs/EAGs significantly correlated with all four hypoxia gene set scores. For more results, please go to download page.

ID_events

cancer

Type

Buffa_P

Buffa_R

Ragnum_P

Ragnum_R

Winter_P

Winter_R

HALLMARK_P

HALLMARK_R

CorrelationPlot

Top

Associations of enriched editing regions with hallmark gene sets from MSigDB.

* P<0.05 and Informative number >=20.

* EER: enriched editing region, EAG: EER-associated genes.

* Only shows the most significant correlation result of EERs/EAGs with the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.

ID_events	cancer	HallmarkType	Type	P	R	CorrelationPlot
ENSG00000254470.2,AP5B1	ACC	GSVA_HALLMARK_TGF_BETA_SIGNALING	EAG	3.2627e-02	-0.4048
chr11:65775899-65777113:-	ACC	GSVA_HALLMARK_TGF_BETA_SIGNALING	EER	3.2627e-02	-0.4048
ENSG00000254470.2,AP5B1	BLCA	GSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAY	EAG	2.1131e-05	0.2548
chr11:65775899-65777113:-	BLCA	GSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAY	EER	2.1131e-05	0.2548
ENSG00000254470.2,AP5B1	BRCA	GSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATION	EAG	1.3887e-08	0.1853
chr11:65775899-65777113:-	BRCA	GSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATION	EER	1.3887e-08	0.1853
chr11:65775899-65777113:-	CESC	GSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATION	EER	2.5980e-03	0.2026
ENSG00000254470.2,AP5B1	CESC	GSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATION	EAG	2.5980e-03	0.2026
ENSG00000254470.2,AP5B1	CHOL	GSVA_HALLMARK_PANCREAS_BETA_CELLS	EAG	8.8651e-03	0.4937
chr11:65775899-65777113:-	CHOL	GSVA_HALLMARK_PANCREAS_BETA_CELLS	EER	8.8651e-03	0.4937
chr11:65775899-65777113:-	COAD	GSVA_HALLMARK_MITOTIC_SPINDLE	EER	2.0375e-05	-0.2874
ENSG00000254470.2,AP5B1	COAD	GSVA_HALLMARK_MITOTIC_SPINDLE	EAG	2.0375e-05	-0.2874
ENSG00000254470.2,AP5B1	ESCA	GSVA_HALLMARK_MYOGENESIS	EAG	3.6571e-02	0.1654
chr11:65775899-65777113:-	ESCA	GSVA_HALLMARK_MYOGENESIS	EER	3.6571e-02	0.1654
ENSG00000254470.2,AP5B1	GBM	GSVA_HALLMARK_ADIPOGENESIS	EAG	5.4994e-06	0.4095
chr11:65775899-65777113:-	GBM	GSVA_HALLMARK_ADIPOGENESIS	EER	5.4994e-06	0.4095
chr11:65775899-65777113:-	HNSC	GSVA_HALLMARK_DNA_REPAIR	EER	1.6845e-04	0.1819
ENSG00000254470.2,AP5B1	HNSC	GSVA_HALLMARK_DNA_REPAIR	EAG	1.6845e-04	0.1819
ENSG00000254470.2,AP5B1	KICH	GSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAY	EAG	7.2854e-03	0.3403
chr11:65775899-65777113:-	KICH	GSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAY	EER	7.2854e-03	0.3403
ENSG00000254470.2,AP5B1	KIRC	GSVA_HALLMARK_HEME_METABOLISM	EAG	6.0024e-05	-0.2224
chr11:65775899-65777113:-	KIRC	GSVA_HALLMARK_HEME_METABOLISM	EER	6.0024e-05	-0.2224
ENSG00000254470.2,AP5B1	KIRP	GSVA_HALLMARK_MITOTIC_SPINDLE	EAG	4.6047e-06	-0.3020
chr11:65775899-65777113:-	KIRP	GSVA_HALLMARK_MITOTIC_SPINDLE	EER	4.6047e-06	-0.3020
chr11:65775899-65777113:-	LAML	GSVA_HALLMARK_CHOLESTEROL_HOMEOSTASIS	EER	1.7072e-03	-0.2583
ENSG00000254470.2,AP5B1	LAML	GSVA_HALLMARK_CHOLESTEROL_HOMEOSTASIS	EAG	1.7072e-03	-0.2583
ENSG00000254470.2,AP5B1	LGG	GSVA_HALLMARK_UV_RESPONSE_DN	EAG	4.7083e-07	-0.2340
chr11:65775899-65777113:-	LGG	GSVA_HALLMARK_UV_RESPONSE_DN	EER	4.7083e-07	-0.2340
ENSG00000254470.2,AP5B1	LIHC	GSVA_HALLMARK_FATTY_ACID_METABOLISM	EAG	1.7285e-02	0.2046
chr11:65775899-65777113:-	LIHC	GSVA_HALLMARK_FATTY_ACID_METABOLISM	EER	1.7285e-02	0.2046
chr11:65775899-65777113:-	LUAD	GSVA_HALLMARK_MYC_TARGETS_V1	EER	4.2868e-04	0.1650
ENSG00000254470.2,AP5B1	LUAD	GSVA_HALLMARK_MYC_TARGETS_V1	EAG	4.2868e-04	0.1650
chr11:65775899-65777113:-	LUSC	GSVA_HALLMARK_MITOTIC_SPINDLE	EER	7.8149e-06	-0.2056
ENSG00000254470.2,AP5B1	LUSC	GSVA_HALLMARK_MITOTIC_SPINDLE	EAG	7.8149e-06	-0.2056
ENSG00000254470.2,AP5B1	OV	GSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATION	EAG	2.4711e-05	0.2675
chr11:65775899-65777113:-	OV	GSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATION	EER	2.4711e-05	0.2675
ENSG00000254470.2,AP5B1	PAAD	GSVA_HALLMARK_PROTEIN_SECRETION	EAG	4.9305e-05	-0.3431
chr11:65775899-65777113:-	PAAD	GSVA_HALLMARK_PROTEIN_SECRETION	EER	4.9305e-05	-0.3431
ENSG00000254470.2,AP5B1	PCPG	GSVA_HALLMARK_KRAS_SIGNALING_DN	EAG	4.4917e-02	0.2131
chr11:65775899-65777113:-	PCPG	GSVA_HALLMARK_KRAS_SIGNALING_DN	EER	4.4917e-02	0.2131
chr11:65775899-65777113:-	PRAD	GSVA_HALLMARK_MITOTIC_SPINDLE	EER	9.7196e-04	-0.1850
ENSG00000254470.2,AP5B1	PRAD	GSVA_HALLMARK_MITOTIC_SPINDLE	EAG	9.7196e-04	-0.1850
ENSG00000254470.2,AP5B1	READ	GSVA_HALLMARK_MITOTIC_SPINDLE	EAG	3.2505e-02	-0.2440
chr11:65775899-65777113:-	SARC	GSVA_HALLMARK_BILE_ACID_METABOLISM	EER	7.8534e-05	0.3118
ENSG00000254470.2,AP5B1	SARC	GSVA_HALLMARK_BILE_ACID_METABOLISM	EAG	7.8534e-05	0.3118
ENSG00000254470.2,AP5B1	SKCM	GSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALING	EAG	2.7126e-04	-0.1754
chr11:65775899-65777113:-	SKCM	GSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALING	EER	2.7126e-04	-0.1754
ENSG00000254470.2,AP5B1	STAD	GSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATION	EAG	1.0914e-05	0.2324
chr11:65775899-65777113:-	STAD	GSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATION	EER	1.0914e-05	0.2324
ENSG00000254470.2,AP5B1	TGCT	GSVA_HALLMARK_HYPOXIA	EAG	3.3360e-02	-0.2956
ENSG00000254470.2,AP5B1	THCA	GSVA_HALLMARK_PROTEIN_SECRETION	EAG	5.7595e-11	-0.3056
chr11:65775899-65777113:-	THCA	GSVA_HALLMARK_PROTEIN_SECRETION	EER	5.7595e-11	-0.3056
ENSG00000254470.2,AP5B1	THYM	GSVA_HALLMARK_INTERFERON_ALPHA_RESPONSE	EAG	8.5020e-03	0.3288
chr11:65775899-65777113:-	THYM	GSVA_HALLMARK_INTERFERON_ALPHA_RESPONSE	EER	8.5020e-03	0.3288
ENSG00000254470.2,AP5B1	UCEC	GSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALING	EAG	3.5255e-03	-0.2981
chr11:65775899-65777113:-	UCEC	GSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALING	EER	3.5255e-03	-0.2981
chr11:65775899-65777113:-	UVM	GSVA_HALLMARK_MITOTIC_SPINDLE	EER	3.8345e-02	-0.2335
ENSG00000254470.2,AP5B1	UVM	GSVA_HALLMARK_MITOTIC_SPINDLE	EAG	3.8345e-02	-0.2335

Top

7. Enriched editing regions and drugs for AP5B1

Correlations between enriched editing regions and drug sensitivity.

* First, the drug sensitivity (IS50) was estimated on 84 drugs by pRRophetic package.

* Second, the correlations between editing enriched regions and drug sensitivity were analyzed (P<0.05 and Informative number >=20).

* EER: enriched editing region, EAG: EER-associated genes.

* Only shows the most significant correlation result of EERs/EAGs with the IS50 scores of 84 drugs according to correlation coefficient (R). For more results, please go to download page.

ID_events	cancer	Drug	Type	P	R	CorrelationPlot
chr11:65775899-65777113:-	ACC	Lapatinib	EER	1.8440e-02	0.4423
ENSG00000254470.2,AP5B1	ACC	Lapatinib	EAG	1.8440e-02	0.4423
ENSG00000254470.2,AP5B1	BLCA	BMS.536924	EAG	1.3973e-04	-0.2289
chr11:65775899-65777113:-	BLCA	BMS.536924	EER	1.3973e-04	-0.2289
chr11:65775899-65777113:-	BRCA	A.443654	EER	6.0543e-05	-0.1315
ENSG00000254470.2,AP5B1	BRCA	A.443654	EAG	6.0543e-05	-0.1315
ENSG00000254470.2,AP5B1	CESC	BMS.536924	EAG	6.6014e-03	-0.1831
chr11:65775899-65777113:-	CESC	BMS.536924	EER	6.6014e-03	-0.1831
ENSG00000254470.2,AP5B1	CHOL	BMS.509744	EAG	4.6204e-02	-0.3869
chr11:65775899-65777113:-	CHOL	BMS.509744	EER	4.6204e-02	-0.3869
chr11:65775899-65777113:-	COAD	IPA.3	EER	7.9460e-03	0.1814
ENSG00000254470.2,AP5B1	COAD	IPA.3	EAG	7.9460e-03	0.1814
ENSG00000254470.2,AP5B1	DLBC	AUY922	EAG	4.5223e-02	-0.4310
chr11:65775899-65777113:-	DLBC	AUY922	EER	4.5223e-02	-0.4310
ENSG00000254470.2,AP5B1	ESCA	GSK269962A	EAG	5.9163e-05	-0.3120
chr11:65775899-65777113:-	ESCA	GSK269962A	EER	5.9163e-05	-0.3120
chr11:65775899-65777113:-	GBM	JNK.Inhibitor.VIII	EER	1.1664e-04	0.3516
ENSG00000254470.2,AP5B1	GBM	JNK.Inhibitor.VIII	EAG	1.1664e-04	0.3516
ENSG00000254470.2,AP5B1	HNSC	AKT.inhibitor.VIII	EAG	1.0436e-04	0.1875
chr11:65775899-65777113:-	HNSC	AKT.inhibitor.VIII	EER	1.0436e-04	0.1875
chr11:65775899-65777113:-	KICH	BI.D1870	EER	7.3070e-03	-0.3402
ENSG00000254470.2,AP5B1	KICH	BI.D1870	EAG	7.3070e-03	-0.3402
ENSG00000254470.2,AP5B1	KIRC	GSK269962A	EAG	8.5740e-07	-0.2710
chr11:65775899-65777113:-	KIRC	GSK269962A	EER	8.5740e-07	-0.2710
ENSG00000254470.2,AP5B1	KIRP	AZD6482	EAG	2.6692e-04	0.2424
chr11:65775899-65777113:-	KIRP	AZD6482	EER	2.6692e-04	0.2424
chr11:65775899-65777113:-	LAML	IPA.3	EER	4.2232e-06	-0.3715
ENSG00000254470.2,AP5B1	LAML	IPA.3	EAG	4.2232e-06	-0.3715
chr11:65775899-65777113:-	LGG	BMS.509744	EER	5.8637e-04	-0.1609
ENSG00000254470.2,AP5B1	LGG	BMS.509744	EAG	5.8637e-04	-0.1609
ENSG00000254470.2,AP5B1	LIHC	CEP.701	EAG	4.7412e-02	-0.1710
chr11:65775899-65777113:-	LIHC	CEP.701	EER	4.7412e-02	-0.1710
chr11:65775899-65777113:-	LUAD	Bexarotene	EER	1.9739e-03	0.1452
ENSG00000254470.2,AP5B1	LUAD	Bexarotene	EAG	1.9739e-03	0.1452
chr11:65775899-65777113:-	LUSC	BMS.536924	EER	3.9794e-05	-0.1893
ENSG00000254470.2,AP5B1	LUSC	BMS.536924	EAG	3.9794e-05	-0.1893
chr11:65775899-65777113:-	MESO	BMS.708163	EER	8.7296e-03	-0.3180
ENSG00000254470.2,AP5B1	MESO	BMS.708163	EAG	8.7296e-03	-0.3180
ENSG00000254470.2,AP5B1	OV	Bexarotene	EAG	2.7544e-03	0.1917
chr11:65775899-65777113:-	OV	Bexarotene	EER	2.7544e-03	0.1917
ENSG00000254470.2,AP5B1	PCPG	Axitinib	EAG	2.6596e-03	0.3148
chr11:65775899-65777113:-	PCPG	Axitinib	EER	2.6596e-03	0.3148
ENSG00000254470.2,AP5B1	PRAD	BMS.509744	EAG	1.2944e-03	-0.1805
chr11:65775899-65777113:-	PRAD	BMS.509744	EER	1.2944e-03	-0.1805
ENSG00000254470.2,AP5B1	READ	ATRA	EAG	5.6282e-04	0.3841
ENSG00000254470.2,AP5B1	SARC	CMK	EAG	1.2611e-03	0.2567
chr11:65775899-65777113:-	SARC	CMK	EER	1.2611e-03	0.2567
ENSG00000254470.2,AP5B1	SKCM	Camptothecin	EAG	4.6744e-06	-0.2195
chr11:65775899-65777113:-	SKCM	Camptothecin	EER	4.6744e-06	-0.2195
ENSG00000254470.2,AP5B1	STAD	AG.014699	EAG	1.0577e-03	0.1741
chr11:65775899-65777113:-	STAD	AG.014699	EER	1.0577e-03	0.1741
ENSG00000254470.2,AP5B1	TGCT	BMS.509744	EAG	3.3135e-02	0.2960
chr11:65775899-65777113:-	THCA	BMS.536924	EER	8.8985e-14	-0.3455
ENSG00000254470.2,AP5B1	THCA	BMS.536924	EAG	8.8985e-14	-0.3455
ENSG00000254470.2,AP5B1	UCEC	Gefitinib	EAG	4.9045e-03	-0.2879
chr11:65775899-65777113:-	UCEC	Gefitinib	EER	4.9045e-03	-0.2879
ENSG00000254470.2,AP5B1	UVM	FTI.277	EAG	1.6109e-02	0.2700
chr11:65775899-65777113:-	UVM	FTI.277	EER	1.6109e-02	0.2700

Top

EAGs targeted by drugs from DrugBank database.

* EAG: EER-associated genes.

EER

ENST

UniprotID

DrugBankID

Drug

DrugType